[Pleural effusion induced by bromocriptine].
Bromocriptine, a derivative of ergot of rye, is used in high doses for the treatment of Parkinson's disease and may be responsible for pleuro-pulmonary complications. We report a case of a 72 year old patient treated for 2 years for Parkinson's disease with a daily dose of 30 mgms. of bromocriptine and in whom a pleural effusion, initially unilateral then bilateral, was discovered with a deterioration in the general physical state. The effusion was a transudate and examination did not give any clues as to aetiology, there was a rapidly favourable outcome following the cessation of treatment. Amongst the respiratory complications of bromocriptine it is the pleuro-pulmonary fibrosis which is most frequently reported. The cases of isolated pleural effusions are rare and are generally exudates. Several hypotheses have been put forward to explain the pathogenesis of these disorders: there is a theory that the molecule induces a toxic fibrogenesis, there is a vascular theory analogous with the secondary effects of methysergide and finally immunological theory. The frequency of the disorder is probably underestimated and these drug reactions justify a close follow up for any respiratory problems in patients who are subjected to treatment with bromocriptine.
Diot
E
E
Service de Médecine B, CHU Bretonneau, Tours.
Diot
P
P
Le Rolland
A
A
Jonville
A P
AP
Lasfargues
G
G
Lemarie
E
E
Lavandier
M
M
Guilmot
J L
JL
D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects*; D006801:Humans; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy; D010996:Pleural Effusion / Q000139:chemically induced*
D001971:Bromocriptine
Epanchements pleuraux induits par la bromocriptine.